NAD+ Injections: IV vs Subcutaneous, Tolerability, and What the Benefits Evidence Shows

This article is educational and written for licensed prescribers. It is not medical advice, and it does not recommend a dose for any patient.

An NAD+ injection delivers nicotinamide adenine dinucleotide directly into the body, bypassing the gut. That route choice is the whole point: intact NAD+ is poorly absorbed when swallowed and is largely broken down to nicotinamide before it reaches circulation. Injection — by IV infusion or by subcutaneous shot — is how NAD+ is given when the goal is to deliver the molecule itself rather than a precursor. This guide covers the routes, why tolerability depends so heavily on how fast NAD+ goes in, and what the evidence does and does not show about NAD+ injection benefits.

For what NAD+ does in the cell and why levels decline with age, see our NAD+ overview. If you are weighing injections against oral NMN, see NAD+ vs NMN.

Why NAD+ Is Given by Injection

NAD+ is a large, charged dinucleotide. Taken orally, it does not survive the gut intact in meaningful amounts. That leaves two strategies for raising NAD+:

1. Give NAD+ parenterally, so the intact molecule reaches circulation.
2. Give an oral precursor (NMN or NR), which is absorbed and converted to NAD+ through the salvage pathway.

The injectable route is a workaround for a chemistry problem, not evidence that injection is inherently superior. It produces a larger, faster increase; oral precursors are easier to sustain day to day.

NAD+ Injection Routes Compared

The following is educational context on how NAD+ is administered in practice. It is not a dosing recommendation; amounts and schedules are set by the prescriber.

IV Infusion

IV NAD+ is the most established parenteral route. Infusions are deliberately slow — commonly several hours — because giving NAD+ quickly reliably produces chest pressure, abdominal cramping, nausea, flushing, and headache. These effects are rate-dependent: they ease when the infusion is slowed, which is why IV NAD+ needs supervision and why "rapid push" administration is inappropriate.

The practical cost is time. Multi-hour sessions, often repeated across a course, are the main barrier to IV NAD+ for many patients.

Subcutaneous Injection

Subcutaneous NAD+ uses much smaller per-dose amounts than an infusion, with correspondingly milder acute effects. Injection-site stinging or discomfort is the most common complaint. It is often used for maintenance between infusion courses, or by patients who cannot commit to repeated infusions. For technique, see how to inject peptides; the same subcutaneous principles apply even though NAD+ is not a peptide.

NAD+ Injection Benefits: What the Evidence Shows

Claims about NAD+ injection benefits range from well-supported biochemistry to marketing that runs well ahead of the data. It helps to separate them.

The consistent finding across the NAD+ literature is that raising NAD+ is demonstrable, while translating that increase into outcomes patients can feel or clinicians can measure is not settled. Much of the human trial evidence comes from oral precursor studies rather than injected NAD+ itself. Precursor trials have reported variable and often modest effects on insulin sensitivity, muscle function, and inflammatory markers, differing by population, dose, and duration.

That does not mean injections are pointless. It means the reasonable case for them is narrower than the marketing: a faster, larger acute increase for patients and prescribers who want that specifically, without a promise of clinical anti-aging effects.

Safety and Monitoring

Rate-Dependent Effects

The dominant safety consideration for IV NAD+ is infusion rate. Chest pressure, cramping, nausea, flushing, and headache are uncomfortable rather than dangerous when managed by slowing the infusion, but they are the reason infusions must be supervised.

Methylation

Nicotinamide is cleared through methylation, which consumes S-adenosylmethionine. Whether sustained high-dose NAD+ or precursor use meaningfully depletes methyl donors is debated; some clinicians monitor or co-supplement accordingly.

Populations Requiring Caution

• Active malignancy. NAD+ supports DNA repair and cellular energetics in all cells, including tumor cells, and the implications are unresolved. Patients on chemotherapy should not start NAD+ protocols without oncology input.
• Pregnancy and lactation. Data are lacking.
• Product quality. Injectable NAD+ must be sterile. Beyond-use dating is set by the compounding pharmacy; see peptide storage for general handling principles.

Regulatory Status

As of the site's FDA peptide status tracker, injectable NAD+ is listed in Category 1 — under evaluation. Category 1 status is interim and applies to the nominated form, so check the tracker for the current position and confirm availability with the compounding partner.

NAD+ often appears alongside other mitochondrial compounds such as methylene blue and SS-31; see our guide to anti-aging peptides for how these fit together.

Newtropin does not prescribe, compound, or dispense. We connect licensed providers with a licensed 503A compounding partner; prescribers can start at For Providers.

Frequently Asked Questions

What is an NAD+ injection?

An NAD+ injection delivers nicotinamide adenine dinucleotide by IV infusion or by subcutaneous or intramuscular injection. Injection is used because intact NAD+ is poorly absorbed when taken orally.

What are the benefits of NAD+ injections?

Injection reliably raises circulating NAD+, which is required for sirtuin activity and mitochondrial energy production. Whether that increase produces measurable clinical benefit in healthy adults has not been established; trial results so far are variable and generally modest.

Why do NAD+ IV infusions take so long?

Giving NAD+ quickly reliably causes chest tightness, cramping, nausea, and flushing. These effects depend on the infusion rate, so infusions are run slowly — commonly over several hours — under supervision.

Are subcutaneous NAD+ injections as effective as IV?

They use smaller per-dose amounts and produce milder acute effects. There is no well-powered trial comparing clinical outcomes between subcutaneous and IV NAD+.

Is NAD+ legal to compound?

As of the site's July 2026 tracker, injectable NAD+ is listed in Category 1, under evaluation. The designation is interim, so check the tracker and confirm with the compounding partner.

Are NAD+ injections safe?

The most common effects are infusion-rate discomfort with IV use and injection-site discomfort with subcutaneous use. Patients with active cancer, pregnant patients, and those on chemotherapy need specific caution.